Price History

Hover for the daily close. The dotted line marks the period open.

Compare TLPH with… →

TLPH Key Statistics

As of Sep 4, 2026

Trading

Open: $1.20
Previous Close: $1.20
Day's Range: 1.20–1.21
52-Week Range: 0.56–1.57
Volume: 58.90K
Beta: 0.69

Valuation

Market Cap: $62.29M
P/E Ratio: unprofitable
EPS (ttm): −0.23

Financials (FY)

Revenue (FY): $28.00K
Net Income (FY): −$14.29M
Profit margin: 0.00%
Shares Outstanding: 51.91M
1-Year Return: +130.77%

Dividend and dates

Earnings Date: November 11, 2026
Avg Volume: 328.54K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TLPH Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−79.82%+119.23%+5.26%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+5.26%
2025	+119.23%
2024	−29.73%
2023	−67.26%
2022	−79.82%
2021	−54.84%
2020	−41.23%
2019	−8.66%
2018	+13.79%
2017	−21.92%
2016 (partial year)	−27.58%

As of September 4, 2026.

TLPH Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$28.00K	−$14.29M	−51035.7%
2024	$0.00	−$13.00M	—
2023	$651.00K	−$18.40M	−2826.0%
2022	$0.00	$47.76M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$28.00K	—	−$13.48M	−$14.29M	−51035.7%
2024	$0.00	—	−$15.25M	−$13.00M	—
2023	$651.00K	—	−$16.89M	−$18.40M	−2826.0%
2022	$0.00	−$820.00K	−$20.35M	$47.76M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TLPH Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks

Metric	TLPH	Drug Manufacturers - Specialty & Generic median	vs median
Profit margin	0.00%	−3.14%	3.1 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Talphera, Inc. (TLPH) is capitalised at $62.29M on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 12 employees.

Over the past 52 weeks the price has ranged from $0.56 to $1.57. The most recent close on file for TLPH is $1.20, dated September 4, 2026. The close was unchanged from the previous session. The latest close sits 114.29% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $28.00K. The same year closed with a net loss of $14.29M. Profit margin runs at 0%. That is 3.1 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.23.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $28.00K in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.69. Annualized volatility over the trailing 10 years is 93.75%. The trailing one-year price return is +130.77%. Across 10 years the annualized return works out at −32.58%.

Growth & Income

No dividend is on file for TLPH.

Across the complete calendar years on file, 2025 returned +119.23% and 2022 returned −79.82%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the price is +5.26% year to date.

Peer Comparison

Talphera, Inc. (TLPH) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Talphera, Inc.	TLPH	$62.29M	—
Takeda Pharmaceutical Company Limited	TAK	$58.92B	—
Teva Pharmaceutical Industries Limited	TEVA	$42.37B	60.6
Haleon plc	HLN	$42.22B	20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Talphera, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

TEVA

Teva Pharmaceutical Industries Limited

$42.37B

HLN

Haleon plc

$42.22B

ZTS

Zoetis Inc.

$31.33B

UTHR

United Therapeutics Corporation

$20.91B

VTRS

Viatris Inc.

$19.39B

View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Talphera, Inc.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Visit website →

Talphera, Inc. (TLPH) Stock Analysis